EMA committee recommends approval of AbbVie's risankizumab to treat moderately to severely active ulcerative colitis
AbbVie announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of risankizumab (Skyrizi) for the treatment of adults with moderately to …